Mario Occhipinti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
P50.06 First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate	JOURNAL OF THORACIC ONCOLOGY	2021
1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy	ANNALS OF ONCOLOGY	2021
1236P Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation	ANNALS OF ONCOLOGY	2021
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification	ANNALS OF ONCOLOGY	2020
The 5-Ws of immunotherapy in head and neck cancer	CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY	2020
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden	ANNALS OF ONCOLOGY	2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer. The multicenter “SLAVE” study	CANCERS	2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	CLINICAL LUNG CANCER	2020
Is hyperprogressive disease a specific phenomenom of immunotherapy?	EXPLORATION OF TARGETED ANTI-TUMOR THERAPY	2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study	ADVANCES IN THERAPY	2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab	EXPERT OPINION ON BIOLOGICAL THERAPY	2020
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer. The multicenter “SLAVE” study	CANCERS	2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: A multicenter study with external validation	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study	ONCOIMMUNOLOGY	2020
AIOM abstracts - IMPACT OF MULTIDISCIPLINARY BASELINE EVALUATION FOR THYMIC EPITHELIAL TUMORS: EXPERIENCE FROM AN ITALIAN REFERENCE CENTER	TUMORI	2020
1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program	ANNALS OF ONCOLOGY	2020
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer	LUNG CANCER MANAGEMENT	2020
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden	ANNALS OF ONCOLOGY	2020